Cargando…
Evaluation and comparison of short chain fatty acids composition in gut diseases
BACKGROUND: An altered (dysbiosis) and unhealthy status of the gut microbiota is usually responsible for a reduction of short chain fatty acids (SCFAs) concentration. SCFAs obtained from the carbohydrate fermentation processes are crucial in maintaining gut homeostasis and their determination in sto...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767983/ https://www.ncbi.nlm.nih.gov/pubmed/31576099 http://dx.doi.org/10.3748/wjg.v25.i36.5543 |
_version_ | 1783455032319934464 |
---|---|
author | Niccolai, Elena Baldi, Simone Ricci, Federica Russo, Edda Nannini, Giulia Menicatti, Marta Poli, Giovanni Taddei, Antonio Bartolucci, Gianluca Calabrò, Antonino Salvatore Stingo, Francesco Claudio Amedei, Amedeo |
author_facet | Niccolai, Elena Baldi, Simone Ricci, Federica Russo, Edda Nannini, Giulia Menicatti, Marta Poli, Giovanni Taddei, Antonio Bartolucci, Gianluca Calabrò, Antonino Salvatore Stingo, Francesco Claudio Amedei, Amedeo |
author_sort | Niccolai, Elena |
collection | PubMed |
description | BACKGROUND: An altered (dysbiosis) and unhealthy status of the gut microbiota is usually responsible for a reduction of short chain fatty acids (SCFAs) concentration. SCFAs obtained from the carbohydrate fermentation processes are crucial in maintaining gut homeostasis and their determination in stool samples could provide a faster, reliable and cheaper method to highlight the presence of an intestinal dysbiosis and a biomarker for various gut diseases. We hypothesize that different intestinal diseases, such as celiac disease (CD), adenomatous polyposis (AP) and colorectal cancer (CRC) could display a particular fecal SCFAs’ signature. AIM: To compare the fecal SCFAs’ profiles of CD, AP, CRC patients and healthy controls, using the same analytical method. METHODS: In this cross-sectional study, we defined and compared the SCFAs’ concentration in fecal samples of 9 AP, 16 CD, 19 CRC patients and 16 healthy controls (HC). The SCFAs’ analysis were performed using a gas-chromatography coupled with mass spectrometry method. Data analysis was carried out using Wilcoxon rank-sum test to assess pairwise differences of SCFAs’ profiles, partial least squares-discriminate analysis (PLS-DA) to determine the status membership based on distinct SCFAs’ profiles, and Dirichlet regression to determine factors influencing concentration levels of SCFAs. RESULTS: We have not observed any difference in the SCFAs’ amount and composition between CD and healthy control. On the contrary, the total amount of SCFAs was significantly lower in CRC patients compared to HC (P = 0.044) and CD (P = 0.005). Moreover, the SCFAs’ percentage composition was different in CRC and AP compared to HC. In detail, HC displayed higher percentage of acetic acid (P value = 1.3 × 10(-6)) and a lower amount of butyric (P value = 0.02192), isobutyric (P value = 7.4 × 10(-5)), isovaleric (P value = 0.00012) and valeric (P value = 0.00014) acids compared to CRC patients. AP showed a lower abundance of acetic acid (P value = 0.00062) and higher percentages of propionic (P value = 0.00433) and isovaleric (P value = 0.00433) acids compared to HC. Moreover, AP showed higher levels of propionic acid (P value = 0.03251) and a lower level of isobutyric acid (P value = 0.00427) in comparison to CRC. The PLS-DA model demonstrated a significant separation of CRC and AP groups from HC, although some degree of overlap was observed between CRC and AP. CONCLUSION: Analysis of fecal SCFAs shows the potential to provide a non-invasive means of diagnosis to detect patients with CRC and AP, while CD patients cannot be discriminated from healthy subjects. |
format | Online Article Text |
id | pubmed-6767983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-67679832019-10-01 Evaluation and comparison of short chain fatty acids composition in gut diseases Niccolai, Elena Baldi, Simone Ricci, Federica Russo, Edda Nannini, Giulia Menicatti, Marta Poli, Giovanni Taddei, Antonio Bartolucci, Gianluca Calabrò, Antonino Salvatore Stingo, Francesco Claudio Amedei, Amedeo World J Gastroenterol Observational Study BACKGROUND: An altered (dysbiosis) and unhealthy status of the gut microbiota is usually responsible for a reduction of short chain fatty acids (SCFAs) concentration. SCFAs obtained from the carbohydrate fermentation processes are crucial in maintaining gut homeostasis and their determination in stool samples could provide a faster, reliable and cheaper method to highlight the presence of an intestinal dysbiosis and a biomarker for various gut diseases. We hypothesize that different intestinal diseases, such as celiac disease (CD), adenomatous polyposis (AP) and colorectal cancer (CRC) could display a particular fecal SCFAs’ signature. AIM: To compare the fecal SCFAs’ profiles of CD, AP, CRC patients and healthy controls, using the same analytical method. METHODS: In this cross-sectional study, we defined and compared the SCFAs’ concentration in fecal samples of 9 AP, 16 CD, 19 CRC patients and 16 healthy controls (HC). The SCFAs’ analysis were performed using a gas-chromatography coupled with mass spectrometry method. Data analysis was carried out using Wilcoxon rank-sum test to assess pairwise differences of SCFAs’ profiles, partial least squares-discriminate analysis (PLS-DA) to determine the status membership based on distinct SCFAs’ profiles, and Dirichlet regression to determine factors influencing concentration levels of SCFAs. RESULTS: We have not observed any difference in the SCFAs’ amount and composition between CD and healthy control. On the contrary, the total amount of SCFAs was significantly lower in CRC patients compared to HC (P = 0.044) and CD (P = 0.005). Moreover, the SCFAs’ percentage composition was different in CRC and AP compared to HC. In detail, HC displayed higher percentage of acetic acid (P value = 1.3 × 10(-6)) and a lower amount of butyric (P value = 0.02192), isobutyric (P value = 7.4 × 10(-5)), isovaleric (P value = 0.00012) and valeric (P value = 0.00014) acids compared to CRC patients. AP showed a lower abundance of acetic acid (P value = 0.00062) and higher percentages of propionic (P value = 0.00433) and isovaleric (P value = 0.00433) acids compared to HC. Moreover, AP showed higher levels of propionic acid (P value = 0.03251) and a lower level of isobutyric acid (P value = 0.00427) in comparison to CRC. The PLS-DA model demonstrated a significant separation of CRC and AP groups from HC, although some degree of overlap was observed between CRC and AP. CONCLUSION: Analysis of fecal SCFAs shows the potential to provide a non-invasive means of diagnosis to detect patients with CRC and AP, while CD patients cannot be discriminated from healthy subjects. Baishideng Publishing Group Inc 2019-09-28 2019-09-28 /pmc/articles/PMC6767983/ /pubmed/31576099 http://dx.doi.org/10.3748/wjg.v25.i36.5543 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Observational Study Niccolai, Elena Baldi, Simone Ricci, Federica Russo, Edda Nannini, Giulia Menicatti, Marta Poli, Giovanni Taddei, Antonio Bartolucci, Gianluca Calabrò, Antonino Salvatore Stingo, Francesco Claudio Amedei, Amedeo Evaluation and comparison of short chain fatty acids composition in gut diseases |
title | Evaluation and comparison of short chain fatty acids composition in gut diseases |
title_full | Evaluation and comparison of short chain fatty acids composition in gut diseases |
title_fullStr | Evaluation and comparison of short chain fatty acids composition in gut diseases |
title_full_unstemmed | Evaluation and comparison of short chain fatty acids composition in gut diseases |
title_short | Evaluation and comparison of short chain fatty acids composition in gut diseases |
title_sort | evaluation and comparison of short chain fatty acids composition in gut diseases |
topic | Observational Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767983/ https://www.ncbi.nlm.nih.gov/pubmed/31576099 http://dx.doi.org/10.3748/wjg.v25.i36.5543 |
work_keys_str_mv | AT niccolaielena evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases AT baldisimone evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases AT riccifederica evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases AT russoedda evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases AT nanninigiulia evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases AT menicattimarta evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases AT poligiovanni evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases AT taddeiantonio evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases AT bartoluccigianluca evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases AT calabroantoninosalvatore evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases AT stingofrancescoclaudio evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases AT amedeiamedeo evaluationandcomparisonofshortchainfattyacidscompositioningutdiseases |